News
Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.
Zacks Investment Research on MSN3d
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance CutBiogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...
SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.
Sage Therapeutics reported strong Q1 2025 growth, with ZURZUVAE leading the charge in postpartum depression treatment.
Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback